Mex3a promoter hypomethylation can be utilized to diagnose HBV-associated hepatocellular carcinoma: a randomized controlled trial
The presence of Mex3a promoter hypomethylation in hepatocellular carcinoma can be used as a non-invasive biomarker for the early detection of liver cancer.
Authors
- Yu‐Chen Fan (ORCID: https://orcid.org/0000-0002-9126-679X)
- Yu‐Xin Tian (ORCID: https://orcid.org/0000-0001-8982-3174)
- Jie-Ru Yang
- Kai You Wang (ORCID: https://orcid.org/0000-0002-6170-4744)
- J. Li
- Ying Zhang (ORCID: https://orcid.org/0000-0001-5476-1524)
Institutions
- Shandong University (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.3389/fphar.2024.1325869
- Citations
- 4
- Primary Topic
- Epigenetics and DNA Methylation
- Type
- article
- Field-Weighted Citation Impact
- 0.94
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province